88
Participants
Start Date
April 30, 2015
Primary Completion Date
January 31, 2021
Study Completion Date
January 31, 2021
Intuvax (INN: ilixadencel)
Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.
Sunitinib
Cytostatic/cytotoxic drug: protein kinase inhibitor .
University of Debrecen, Debrecen
Szent-Györgyi Albert Klinikai Központ, Szeged
Duke Cancer Institute, Durham
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda
Centre Hospitalier Universitaire de Toulouse-Hôpital Rangueil, Toulouse
Centre Hospitalier Universitaire d'Angers, Angers
University of Iowa, Iowa City
Health Partners Institute, Saint Paul
University of Illinois, Chicago
Rush University, Chicago
University Hospital Olomouc, Olomouc
Pauls Stradins Clinical University Hospital, Riga
Riga East Clinical University Hospital, Riga
Niepubliczny Zakład Opieki Zdrowotnej Vesalius Sp. z o.o., Krakow
Wojewodzki Szpital Specjalistyczny, Lublin
Military Institute of Medicine, Warsaw
Mazowiecki Szpital Onkologiczny, Wieliszew
Hospital Universitari Germans Trias i Pujol, Badalona
Hospital Clinic de Barcelona, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitari Parc Tauli, Sabadell
Sahlgrenska University Hospital, Gothenburg
Karolinska University Hospital, Huddinge
Umeå University Hospital, Umeå
Uppsala University Hospital, Uppsala
The Churchill Hospital, Oxford
Royal Preston Hospital, Preston
Lead Sponsor
Collaborators (1)
TFS Trial Form Support
INDUSTRY
Accelovance
INDUSTRY
Mendus
INDUSTRY